Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,164.46
+23.01 (+2.02%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
September 11, 2024
Via
Benzinga
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
September 11, 2024
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
Via
News Direct
Prediction: These 2 Companies Will Split Their Stocks by 2027
September 11, 2024
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes.
Via
The Motley Fool
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
September 10, 2024
Via
Benzinga
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
September 09, 2024
Via
Benzinga
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
August 27, 2024
Via
Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
August 23, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
August 20, 2024
Via
Benzinga
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
September 05, 2024
These stocks have generally delivered competitive returns.
Via
The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good.
Via
Talk Markets
10 Bagger Stocks: Can You Find One?
August 23, 2024
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors.
Via
Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
August 20, 2024
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment.
Via
Benzinga
Exposures
Product Safety
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
August 13, 2024
Via
Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
August 08, 2024
Via
Benzinga
Analyst Ratings For Regeneron Pharmaceuticals
August 02, 2024
Via
Benzinga
Alphabet Turns Twenty
August 19, 2024
Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13.
Via
Talk Markets
7 Stocks That Usually Benefit From a Recession
August 13, 2024
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession.
Via
InvestorPlace
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
August 13, 2024
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility.
Via
InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Exposures
Product Safety
3 Healthcare Stocks Positioned for Possible Market Outperformance
August 07, 2024
While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market.
Via
InvestorPlace
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
July 30, 2024
Via
Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
July 29, 2024
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Is Regeneron Pharmaceuticals Due for a Stock Split?
August 03, 2024
Would a stock split help lead Regeneron Pharmaceuticals shares higher?
Via
The Motley Fool
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
August 02, 2024
Apple and Meta had strong results, while AI spending remains robust.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
August 01, 2024
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...
Via
Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
August 01, 2024
A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron.
Via
Investor's Business Daily
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
August 01, 2024
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market...
Via
Benzinga
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
August 01, 2024
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.